ARTBIO Advances Lead Prostate Cancer Radiotherapy With U.S. Cohort Dosing in Phase 1 ARTISAN Trial

New updates have been reported about ARTBIO.

ARTBIO has begun dosing two U.S. patient cohorts in its Phase 1 ARTISAN trial of AB001, the company’s lead 212Pb-based alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC), marking a key clinical execution milestone for the business. The study is enrolling both 177Lu-PSMA–naïve patients and patients previously treated with 177Lu-PSMA targeted therapies, positioning AB001 as a potential option across different stages of the PSMA-targeted treatment pathway. The trial is being run at multiple U.S. sites, with ARTBIO planning to expand the study outside the United States in the second half of 2026, which would broaden its clinical and regulatory footprint and lay groundwork for future global development. AB001, a PSMA-targeted small molecule labeled with lead-212, is the company’s flagship program; its U.S. clinical progress follows FDA clearance of the AB001 Investigational New Drug application in September 2025, enabling ARTBIO to formally initiate human studies.

The ARTISAN Phase 1 trial is designed as an open-label, multi-center study evaluating safety, tolerability, pharmacokinetics, biodistribution, and early anti-tumor activity of AB001 in patients with advanced mCRPC who have limited treatment options. ARTBIO is collaborating with specialized partners including BAMF Health and United Theranostics, which are providing clinical and theranostic infrastructure to support patient access and study execution. ARTBIO’s broader strategy centers on building a pipeline of alpha radioligand therapies based on its AlphaDirect technology, a proprietary 212Pb isolation platform that supports distributed manufacturing and may improve supply reliability for radiopharmaceuticals. With AB001 now actively dosing patients, ARTBIO is transitioning from a purely development-stage story to one with emerging clinical data potential, a critical step for validating its platform, informing future trial design, and underpinning subsequent financing, partnering, or expansion decisions in the radiopharmaceutical oncology market.